Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month High – Should You Buy?

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $111.80 and last traded at $110.5760, with a volume of 709776 shares changing hands. The stock had previously closed at $109.68.

Analyst Ratings Changes

Several equities research analysts have commented on HALO shares. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. TD Cowen boosted their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. UBS Group restated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Price Performance

The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market cap of $12.60 billion, a PE ratio of 33.10, a P/E/G ratio of 0.41 and a beta of 0.88. The company’s 50 day moving average is $95.95 and its 200-day moving average is $78.09.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period last year, the firm earned $1.54 earnings per share. The company’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 18,996 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the transaction, the director directly owned 58,839 shares in the company, valued at $6,339,313.86. This represents a 24.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $107.24, for a total transaction of $2,144,800.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,336,727.20. The trade was a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 91,474 shares of company stock valued at $9,416,633 over the last 90 days. 2.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several large investors have recently modified their holdings of HALO. Bank of America Corp DE acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $214,504,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics during the second quarter worth about $196,540,000. Norges Bank bought a new position in Halozyme Therapeutics in the fourth quarter worth about $128,201,000. Jupiter Topco LLC bought a new position in Halozyme Therapeutics in the second quarter worth about $105,570,000. Finally, Caisse de depot et placement du Quebec acquired a new position in Halozyme Therapeutics in the second quarter valued at approximately $83,940,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.